BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 36576057)

  • 1. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
    Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
    World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
    Loomba R; Lim JK; Patton H; El-Serag HB
    Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
    Margini C; Dufour JF
    Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
    Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
    Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
    Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
    Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
    Seif El Dahan K; Daher D; Singal AG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and risk-stratification of NAFLD-associated HCC.
    Ioannou GN
    J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
    Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
    Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
    Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational HCC screening approaches for patients with NAFLD.
    Singal AG; El-Serag HB
    J Hepatol; 2022 Jan; 76(1):195-201. PubMed ID: 34508791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
    Pocha C; Kolly P; Dufour JF
    Semin Liver Dis; 2015 Aug; 35(3):304-17. PubMed ID: 26378646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.